Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 17/20 | 0.61 |
| ▸ | DRD2 | P14416 | 4/20 | 0.61 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886067 | 0.81 | ADRB2 (0.50) | ADRB2ADRB1DRD2 | |
| SCHEMBL4134772 | 0.76 | ADRB2 (0.64) | ADRB2ADRB1DRD2DRD3ADRA1D | |
| SCHEMBL3890894 | 0.76 | ADRB2 (0.64) | ADRB2ADRB1DRD2DRD3ADRA1D | |
| SCHEMBL4526989 | 0.76 | ADRB2 (1.00) | ADRB2ADRB1DRD2DRD3ADRA1D | |
| SCHEMBL4218708 | 0.75 | ADRB2 (0.95) | ADRB2ADRB1DRD2DRD3ADRA1D | |
| SCHEMBL3958110 | 0.74 | ADRB2 (0.70) | ADRB2ADRB1DRD2DRD3ADRA1D | |
| SCHEMBL4135992 | 0.74 | ADRB2 (0.70) | ADRB2ADRB1DRD2DRD3ADRA1D | |
| SCHEMBL4138687 | 0.73 | ADRB2 (0.72) | ADRB2ADRB1DRD2DRD3ADRA1D | |
| SCHEMBL3954768 | 0.73 | ADRB2 (0.70) | ADRB2ADRB1DRD2DRD3ADRA1D | |
| SCHEMBL3583527 | 0.73 | ADRB2 (0.74) | ADRB2ADRB1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013197-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007102771-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |